Molecular, biochemical, and cellular pharmacology of pemetrexed

Seminars in Oncology

Volumn 29, Issue 6 SUPPL. 18, 2002, Pages 3-17

  Goldman, I David ^a   Zhao, Rongbao ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROFOLATE REDUCTASE; FLUOROURACIL; FOLIC ACID; FOLIC ACID ANTAGONIST; FOLINIC ACID; FOLYLPOLYGLUTAMATE SYNTHASE; FORMATE TETRAHYDROFOLATE LIGASE; HOMOCYSTEINE; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN; N [5 [2 (2 AMINO 1,4,5,6,7,8 HEXAHYDRO 4 OXOPYRIDO[2,3 D]PYRIMIDIN 6 YL)ETHYL] 2 THENOYL]GLUTAMIC ACID; NALPHA (4 AMINO 4 DEOXYPTEROYL) NDELTA HEMIPHTHALOYLORNITHINE; PEMETREXED; PHOSPHORIBOSYLAMINOIMIDAZOLECARBOXAMIDE FORMYLTRANSFERASE; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; PLEVITREXED; POLYGLUTAMIC ACID; PROSTAGLANDIN A1; RALTITREXED; REDUCED FOLATE CARRIER; THYMIDYLATE SYNTHASE; THYMIDYLATE SYNTHASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; CELL MEMBRANE TRANSPORT; CROSS RESISTANCE; DRUG ACCUMULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TRANSPORT; FOLIC ACID DEFICIENCY; HUMAN; LEUKEMIA L 1210; NONHUMAN; PRIORITY JOURNAL; PURINE SYNTHESIS; REVIEW;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; DRUG RESISTANCE, NEOPLASM; FOLIC ACID ANTAGONISTS; GLUTAMATES; GUANINE; HUMANS; LEUCOVORIN; METHOTREXATE; POLYGLUTAMIC ACID; PTEROYLPOLYGLUTAMIC ACIDS; TETRAHYDROFOLATE DEHYDROGENASE; TETRAHYDROFOLATES; THYMIDYLATE SYNTHASE; TUMOR CELLS, CULTURED;

EID: 0036987083     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.37421     Document Type: Review

References (76)

1. Farber S, Diamond LK, Mercer RD, et al: Temporary remission in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl glutamic acid (aminopterin). N Engl J Med 238:787-793, 1948
2. Bertino JR: Ode to methotrexate. J Clin Oncol 11:5-14, 1993
3. Pisetsky DS, St Clair EW: Progress in the treatment of rheumatoid arthritis. JAMA 286:2787-2790, 2001
4. Lebwohl M, Ali S: Treatment of psoriasis. Part 2. Systemic therapies. J Am Acad Dermatol 45:649-661, 2001
5. Picciano MF, Stokstad ELR (eds): Folic Acid Metabolism in Health and Disease. New York, NY, Wiley-Liss, 1990
6. Seither RL, Trent DF, Mikullecky DC, et al: Folate-pool interconversions and inhibition of biosynthetic processes after exposure of L1210 leukemia cells to antifolates. J Biol Chem 264:17016-17023, 1989
7. Goldman ID, Matherly LH: The cellular pharmacology of methotrexate. Pharmacol Ther 28:77-102, 1985
8. Shane B: Folylpolyglutamate synthesis and role in the regulation of one-carbon metabolism. Vitam Horm 45:263-335, 1989
9. Zeng H, Chen ZS, Belinsky MG, et al: Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: Effect of polyglutamylation on MTX transport. Cancer Res 61:7225-7232, 2001
10. Fry DW, Yalowich JC, Goldman ID: Rapid formation of poly-gamma-glutamyl derivatives of methotrexate and their association with dihydrofolate reductase as assessed by high pressure liquid chromatography in the Ehrlich ascited tumor cell in vitro. J Biol Chem 257:1890-1896, 1982
11. Chabner BA, Allegra CJ, Curt GA, et al: Polyglutamation of methotrexate. Is methotrexate a prodrug? J Clin Invest 76:907-912, 1985
12. Allegra CJ, Chabner BA, Drake JC, et al: Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J Biol Chem 260:9720-9726, 1985
13. Allegra CJ, Drake JC, Jolivet J, et al: Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc Natl Acad Sci U S A 82:4881-4885, 1985
14. Fabre I, Fabre G, Goldman ID: Polyglutamylation, an important element in methotrexate cytotoxicity and selectivity in tumor versus murine granulocytic progenitor cells in vitro. Cancer Res 44:3190-3195, 1984
15. Fry DW, Anderson LA, Borst M, et al: Analysis of the role of membrane transport and polyglutamylation of methotrexate in gut and Ehrlich tumor in vivo as factors in drug sensitivity and selectivity. Cancer Res 43:1087-1092, 1983
16. Poser RG, Sirotnak FM, Chello PL: Differential synthesis of methotrexate polyglutamates in normal proliferative and neoplastic mouse tissues in vivo. Cancer Res 41:4441-4446, 1981
17. Goldman ID, Matherly LH: Biochemical factors in the selectivity of leucovorin rescue: Selective inhibition of leucovorin reactivation of dihydrofolate reductase and leucovorin utilization in purine and pyrimidine biosynthesis by methotrexate and dihydrofolate polyglutamates. NCI Monographs 5:17-26, 1987
18. Matherly LH, Barlowe CK, Phillips VM, et al: The effects of 4-aminoantifolates on 5-formyltetrahydrofolate metabolism in L1210 cells. J Biol Chem 262:710-717, 1987
19. Taylor EC, Kuhnt D, Shih C, et al: A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-(2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo(2,3-d)pyrimidin-5-yl) ethyl)benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase. J Med Chem 35:4450-4454, 1992
20. Shih C, Chen VJ, Gossett LS, et al: LY231514, a pyrrolo(2,3-d)pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 57:1116-1123, 1997
21. Schultz RM, Patel VF, Worzalla JF, et al: Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514. Anticancer Res 19:437-443, 1999
22. Zhao R, Babani S, Gao F, et al: The mechanism of transport of the multitargeted antifolate, MTA-LY231514, and its cross resistance pattern in cells with impaired transport of methotrexate. Clin Cancer Res 6:3687-3695, 2000
23. Chen VJ, Bewley JR, Andis SL, et al: Preclinical cellular pharmacology of LY231514 (MTA): A comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells. Br J Cancer 78:27-34, 1998 (suppl 3)
24. Goldman ID: Transport energetics of the folic acid analogue, methotrexate, in L1210 cells: Enhanced accumulation by metabolic inhibitors. J Biol Chem 244:3779-3785, 1969
25. Goldman ID: The characteristics of the membrane transport of amethopterin and the naturally occurring folates. Ann N Y Acad Sci 186:400-422, 1971
26. Goldman ID, Lichtenstein NS, Oliverio VT: Carrier-mediated transport of the folic acid analogue methotrexate, in the L1210 leukemia cell. J Biol Chem 243:5007-5017, 1968
27. Henderson GB, Zevely EM: Structural requirements for anion substrates of the methotrexate transport system of L1210 cells. Arch Biochem Biophys 221:438-446, 1983
28. Yang C-H, Sirotnak FM, Dembo M: Interaction between anions and the reduced folate/methotrexate transport system in L1210 cell plasma membrane vesicles: Directional symmetry and anion specificity for differential mobility of loaded and unloaded carrier. J Membr Biol 79:285-292, 1984
29. Henderson GB: Folate-binding proteins. Annu Rev Nutr 10:319-335, 1990
30. Spinella MJ, Brigle KE, Sierra EE, et al: Distinguishing between folate receptor-α-mediated transport and reduced folate carrier-mediated transport in L1210 leukemia cells. J Biol Chem 270:7842-7849, 1995
31. Westerhof GR, Schornagel JH, Kathmann I, et al: Carrier- and receptor- mediated transport of folate antagonists targeting folate-dependent enzymes: Correlates of molecular-structure and biological activity. Mol Pharmacol 48:459-471, 1995
32. Rajgopal A, Sierra EE, Zhao R, et al: Expression of the reduced folate carrier SLC19A1 in IEC-6 cells results in two distinct transport activities. Am J Physiol Cell Physiol 281: C1579-C1586, 2001
33. Sierra EE, Goldman ID: Characterization of folate transport mediated by a low pH route in mouse L1210 leukemia cells with defective reduced folate carrier function. Biochem Pharmacol 55:1505-1512, 1998
34. Saito H, Masuda S, Inui K: Cloning and functional characterization of a novel rat organic anion transporter mediating basolateral uptake of methotrexate in the kidney. J Biol Chem 271:20719-20725, 1996
35. Masuda S, Ibaramoto K, Takeuchi A, et al: Cloning and functional characterization of a new multispecific organic anion transporter, OAT-K2, in rat kidney. Mol Pharmacol 55: 743-752, 1999
36. Abe T, Unno M, Onogawa T, et al: LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology 120:1689-1699, 2001
37. Sun W, Wu RR, van Poelje PD, et al: Isolation of a family of organic anion transporters from human liver and kidney. Biochem Biophys Res Commun 283:417-422, 2001
38. Cha SH, Sekine T, Fukushima JI, et al: Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol 59: 1277-1286, 2001
39. Schlemmer SR, Sirotnak FM: Energy-dependent efflux of methotrexate in L1210 leukemia cells. Evidence for the role of an ATPase obtained with inside-out plasma membrane vesicles. J Biol Chem 267:14746-14752, 1992
40. Saxena M, Henderson GB: Identification of efflux systems for large anions and anionic conjugates as the mediators of methotrexate efflux in L1210 cells. Biochem Pharmacol 51: 975-982, 1996
41. Kusuhara H, Han YH, Shimoda M, et al: Reduced folate derivatives are endogenous substrates for cMOAT in rats. Am J Physiol 275:G789-G796, 1998
42. Zeng H, Liu G, Rea PA, et al: Transport of amphipathic anions by human multidrug resistance protein 3. Cancer Res 60:4779-4784, 2000
43. Kool M, van der Linden LM, de Haas M, et al: MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci U S A 96:6914-6919, 1999
44. Hirohashi T, Suzuki H, Sugiyama Y: Characterization of the transport properties of cloned rat multidrug resistance-associated protein 3 (MRP3). J Biol Chem 274:15181-15185, 1999
45. Zhao R, Seither R, Brigle KE, et al: Impact of overexpression of the reduced folate carrier (RFC1), an anion exchanger, on concentrative transport in murine L1210 leukemia cells. J Biol Chem 272:21207-21212, 1997
46. Assaraf YG, Goldman ID: Loss of folic acid exporter function with markedly augmented folate accumulation in lipophilic antifolate-resistant mammalian cells. J Biol Chem 272:17460-17466, 1997
47. Habeck LL, Mendelsohn LG, Shih C, et al: Substrate specificity of mammalian folylpolyglutamate synthetase for 5,10-dideazatetrahydrofolate analogs. Mol Pharmacol 48:326-333, 1995
48. Shepherd FA, Dancey J, Arnold A, et al: Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: A study of the National Cancer Institute of Canada Clinical Trials Group. Cancer 92:595-600, 2001
49. Zhao R, Titus S, Gao F, et al: Molecular analysis of murine leukemia cell lines resistant to 5,10-ideazatetrahydrofolate identifies several amino acids critical to the function of folylpolyglutamate synthetase. J Biol Chem 275:26599-26606, 2000
50. Zhao R, Gao F, Goldman ID: Marked suppression of the activity of some, but not all, antifolate compounds by augmentation of folate cofactor pools within tumor cells. Biochem Pharmacol 61:857-865, 2001
51. Jackman AL, Kimbell R, Aherne GW, et al: Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: A water-soluble, nonpolyglutamatable, quinazoline-based inhibftor of thymidylate synthase. Clin Cancer Res 3:911-921, 1997
52. Rosowsky A, Wright JE, Vaidya CM, et al: Synthesis and potent antifolate activity and cytotoxicity of B-ring deaza analogues of the nonpolyglutamatable dihydrofolate reductase inhibitor Nalpha-(4-amino-4-deoxypteroyl)-Ndelta-hemiphaloyl-L-ornithine (PT523). J Med Chem 41:5310-5319, 1998
53. Schultz RM, Chen VJ, Bewley JR, et al: Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs. Semin Oncol 26:68-73, 1999
54. Jackman AL, Kelland LR, Kimbell R, et al: Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines. Br J Cancer 71:914-924, 1995
55. Curtin NJ, Hughes AN: Pemetrexed disodium, a novel antifolate with multiple targets. Lancet Oncol 2:298-306, 2001
56. Rhee MS, Ryan TJ, Galivan J: Glutamyl hydrolase and the multitargeted antifolate LY231514. Cancer Chemother Pharmacol 44:427-432, 1999
57. Guo W, Healey JH, Meyers PA, et al: Mechanisms of methotrexate resistance in osteosarcoma. Clin Cancer Res 5:621-627, 1999
58. Gorlick R, Goker E, Trippett T, et al: Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression. Blood 89:1013-1018, 1997
59. Zhao R, Sharina IG, Goldman ID: Pattern of mutations that results in loss of reduced folate carrier function under antifolate selective pressure augmented by chemical mutagenesis. Mol Pharmacol 56:68-76, 1999
60. Zhao R, Assaraf YG, Goldman ID: A mutated murine reduced folate carrier (RFC1) with increased affinity for folic acid, decreased affinity for methotrexate, and an obligatory anion requirement for transport function. J Biol Chem 273: 19065-19071, 1998
61. Zhao R, Assaraf YG, Goldman ID: A reduced carrier mutation produces substrate-dependent alterations in carrier mobility in murine leukemia cells and methotrexate resistance with conservation of growth in 5-formyltetrahydrofolate. J Biol Chem 273:7873-7879, 1998
62. Zhao R, Gao F, Goldman ID: Discrimination among reduced folates and methotrexate as transport substrates by a phenylalanine substitution for serine within the predicted eighth transmembrane domain of the reduced folate carrier. Biochem Pharmacol 58:1615-1624, 1999
63. Zhao R, Gao F, Babani S, et al: Sensitivity to 5,10-dideazatetrahydrofolate is fully conserved in a murine leukemia cell line highly resistant to methotrexate due to impaired transport mediated by the reduced folate carrier. Clin Cancer Res 6:3304-3311, 2000
64. Matherly, LH, Angeles SM, McGuire JJ: Determinants of the disparate antitumor activities of (6R)-5,10-dideaza-5,6,7,8-tetrahydrofolate and methotrexate toward human lymphoblastic leukemia cells, characterized by severely impaired antifolate membrane transport. Biochem Pharmacol 46:2185-2195, 1993
65. Jansen G, Mauritz R, Drori S, et al: A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance. J Biol Chem 273:30189-30198, 1998
66. Brigle KE, Spinella MJ, Sierra EE, et al: Characterization of a mutation in the reduced folate carrier in a transport defective L1210 murine leukemia cell line. J Biol Chem 270: 22974-22979, 1995
67. Rots MG, Pieters R, Peters GJ, et al: Circumvention of methotrexate resistance in childhood leukemia subtypes by rationally designed antifolates. Blood 94:3121-3128, 1999
68. Alati T, Worzalla JF, Shih C, et al: Augmentation of the therapeutic activity of lometrexol-(6-R)5,10-dideazatetrahydrofolate-by oral folic acid. Cancer Res 56:2331-2335, 1996
69. Worzalla JF, Shih C, Schultz RM: Role of folic acid in modulating the toxicity and efficacy of the multitargeted antifolate, LY231514. Anticancer Res 18:3235-3239, 1998
70. Wedge SR, Laohavinij S, Taylor GA, et al: Clinical pharmacokinetics of the antipurine antifolate (6R)-5,10-dideaza-5,6,7,8-tetrahydrofolic acid (Lometrexol) administered with an oral folic acid supplement. Clin Cancer Res 1:1479-1486, 1995
71. Laohavinij S, Wedge SR, Lind MJ, et al: A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid. Invest New Drugs 14: 325-335, 1996
72. Roberts JD, Poplin EA, Tombes MB, et al: Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluation. Cancer Chemother Pharmacol 45:103-110, 2000
73. Niyikiza C, Baker SD, Seitz DE, et al: Homocysteine and methyhnalonic acid: Markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 1:545-552, 2002
74. Savage DG, Lindenbaum J, Stabler SP, et al: Sensitivity of serum methylmalonic acid and total homocysteine determinations for diagnosing cobalamin and folate deficiencies. Am J Med 96:239-246, 1994
75. Allen RH, Stabler SP, Savage DG, et al: Metabolic abnormalities in cobalamin (vitamin B12) and folate deficiency. FASEB J 7:1344-1353, 1993
76. Wang YH, Goldman ID: Decreased expression of the reduced folate carrier and folylpolyglutamate synthetase are the basis for acquired resistance to pemetrexate in an L1210 murine leukemia cell line. Biochem Pharmacol (in press)